FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC By Ogkologos - March 18, 2026 277 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Maintenance Olaparib in Elderly Patients With a Germline BRCA Mutation and... July 1, 2020 Dwayne Johnson Sends Special “Moana” Message To 3-Yr-Old Battling Cancer. November 21, 2019 Cancer in My Community: Addressing Health Disparities in Brazil July 18, 2023 Cancer Surgery Unexpectedly Canceled for Mother of Two, Who Says It’s... March 31, 2020 Load more HOT NEWS Immunotherapy, Liquid Biopsy, and Treatment Combinations: Research from the 2024 ASCO... ESMO’s Special Consultative Status with United Nations Economic and Social Council... 癌症治疗期间如何保证日常活动的安全和独立执行 EMA Recommends Granting a Marketing Authorisation for Generic Trabectedin
